AI assistant
Sending…
BIO-TECHNE Corp — Director's Dealing 2012
Aug 1, 2012
30718_dirs_2012-08-01_d8106607-13fe-40a8-96f3-17e32d4ecdb6.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: TECHNE CORP /MN/ (TECH)
CIK: 0000842023
Period of Report: 2012-07-27
Reporting Person: VERONNEAU MARCEL (VP Hematology Operations)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2012-07-27 | Stock Option | $74.05 | A | 1097 | Acquired | 2019-07-26 | Common Stock (1097) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 34569 | Direct |
| Common Stock | 6779 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option | $76.15 | 2018-07-27 | Common Stock (1129) | 1129 | Direct |
| Stock Option | $76.15 | 2018-07-27 | Common Stock (20000) | 20000 | Direct |
| Stock Option | $58.4 | 2017-07-29 | Common Stock (1281) | 1281 | Direct |
| Stock Option | $66.25 | 2017-04-29 | Common Stock (10000) | 10000 | Direct |
| Stock Option | $62.46 | 2016-07-23 | Common Stock (494) | 494 | Direct |
| Stock Option | $79.41 | 2015-07-24 | Common Stock (385) | 385 | Direct |
| Stock Option | $56.83 | 2014-07-26 | Common Stock (510) | 510 | Direct |
| Stock Option | $49.43 | 2013-07-26 | Common Stock (567) | 567 | Direct |
| Stock Option | $51.6 | 2012-08-17 | Common Stock (475) | 475 | Direct |
Footnotes
F1: Vested 5,000 each 6/30/12, 6/30/13, 6/30/14, 6/30/15
More from BIO-TECHNE Corp
Regulatory Filings
2026
Jun 1
Interim / Quarterly Report
2026
May 6
Major Shareholding Notification
2026
May 6
Regulatory Filings
2026
May 6
Major Shareholding Notification
2026
Apr 29
Major Shareholding Notification
2026
Mar 26
Director's Dealing
2026
Feb 19
Board/Management Information
2026
Feb 11
Director's Dealing
2026
Feb 5
Interim / Quarterly Report
2026
Feb 4